<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7294518\results\search\country\results.xml">
  <result pre="Rapid decline of Zika virus NS1 antigen-specific antibody responses, northeastern" exact="Brazil" post="Moreira-SotoAndres1de Souza SampaioGilmara2PedrosoCélia2Postigo-HidalgoIgnacio1BerneckBeatrice Sarah3UlbertSebastian3BritesCarlos2NettoEduardo Martins24http://orcid.org/0000-0002-3509-0232DrexlerJan Felixfelix.drexler@charite.de1567[1], [2], grid.8399.b0000 0004"/>
  <result pre="After decades of circulation in Asia, ZIKV was introduced to" exact="Brazil" post="in 2014–2015, associated with a rise in congenital malformations."/>
  <result pre="serologic tests [8]. ZIKV was first detected in 1947 in" exact="Uganda" post="[9]. Later in 2007, ZIKV emerged in the Pacific"/>
  <result pre="emerged in the Pacific island of Yap, in 2013 in" exact="French Polynesia" post="and other Pacific islands and from there expanding to"/>
  <result pre="available found a high-level population exposure reaching from 42% in" exact="French Polynesia" post="and 49% in Martinique, to as much as 63%"/>
  <result pre="Martinique, to as much as 63% in mainland America, specifically" exact="Brazil" post="[5, 13, 14]. If ZIKV confers long-lasting immunity, high"/>
  <result pre="usually extends over a few thousand km2 only. In contrast," exact="Brazil" post="has 210 million inhabitants spread over 8 million km2"/>
  <result pre="Nonetheless, long-term antibody kinetics of individuals infected with ZIKV in" exact="Brazil" post="are largely unknown. Here, we conducted a prospective observational"/>
  <result pre="2015–2016, due to the ultra-rapid ZIKV spread in Salvador, northeastern" exact="Brazil" post="[5]. Brazil acquired millions of ZIKV NS1 antigen-based indirect"/>
  <result pre="to the ultra-rapid ZIKV spread in Salvador, northeastern Brazil [5]." exact="Brazil" post="acquired millions of ZIKV NS1 antigen-based indirect ELISA tests"/>
  <result pre="later, consistent with near-complete lack of ZIKV activity in northeastern" exact="Brazil" post="after the large initial outbreak [5]. As shown in"/>
  <result pre="period, showing a marked decrease in ZIKV overall seroprevalence in" exact="French Polynesia" post="from 37 to 22% and in Fiji from 24"/>
  <result pre="seroprevalence in French Polynesia from 37 to 22% and in" exact="Fiji" post="from 24 to 12% [24]. This decrease was observed"/>
  <result pre="because DENV seroprevalence is as high as 80% in northeastern" exact="Brazil" post="[5] and individuals frequently have multiple DENV infections likely"/>
  <result pre="which exists as a single serotype. Our serologic data from" exact="Brazil" post="are thus consistent with data from Pacific island populations"/>
  <result pre="their potential immune interplay is largely unknown [16, 17]. Since" exact="Brazil" post="has licensed a DENV vaccine, adequate determination of the"/>
  <result pre="Infect Dis201925231131510.3201/eid2502.18016630666934 5.NettoEMMoreira-SotoAPedrosoCHoserCFunkSKucharskiAJRockstrohAKummererBMSampaioGSLuzEVazSNDiasJPBastosFACabralRKistemannTUlbertSde LamballerieXJaenischTBradyOJDrostenCSarnoMBritesCDrexlerJFHigh Zika virus seroprevalence in Salvador, Northeastern" exact="Brazil" post="limits the potential for further outbreaksmBio201786013901-710.1128/mBio.01390-17 6.GooLVanBlarganLADowdKADiamondMSPiersonTCA single mutation"/>
  <result pre="declines and neutralizing antibodies wane in adults following outbreaks in" exact="French Polynesia" post="and FijieLife20202894846010.7554/eLife.48460 25.MarquesETADrexlerJFComplex Scenario of Homotypic and Heterotypic Zika"/>
 </snippets>
</snippetsTree>
